ArticleAntimicrobial agents and chemotherapy2018
Molecular Epidemiology and Mechanism of Sulbactam Resistance in Acinetobacter baumannii Isolates with Diverse Genetic Backgrounds in China.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Epidemiological characteristics and antimicrobial resistance of extensively drug-resistantMicrobiology spectrum · 2025Article
- Inosine reverses multidrug resistance in Gram-negative bacteria carrying mobilized RND-type efflux pump gene clustermSystems · 2024Article
- Portrait of a killer: Uncovering resistance mechanisms and global spread of Acinetobacter baumannii.PLoS pathogens · 2023Article
- Alteration ofMicrobiology spectrum · 2023Article
- Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Biochemical exploration of β-lactamase inhibitors.Frontiers in genetics · 2022Review
- Growth kinetics of multipleF1000Research · 2022Article
- Virulence Potential and Treatment Options of Multidrug-Resistant (MDR)Microorganisms · 2021Review
- Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use.Antibiotics (Basel, Switzerland) · 2021Review
- Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 againstAntibiotics (Basel, Switzerland) · 2021Article
- Bloodstream infections caused by ST2 Acinetobacter baumannii: risk factors, antibiotic regimens, and virulence over 6 years period in China.Antimicrobial resistance and infection control · 2021Article
- Epidemiological Analysis of Multidrug-ResistantFrontiers in public health · 2021Article
- Article
- Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.Current infectious disease reports · 2019Review
- OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains.Antimicrobial agents and chemotherapy · 2019Article
- Hospitalized Pets as a Source of Carbapenem-Resistance.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulbactam is a plausible option for treating
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.